Published in J Cardiovasc Pharmacol on January 01, 1993
SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist. Proc Natl Acad Sci U S A (1994) 1.39
The mechanisms of coronary restenosis: insights from experimental models. Int J Exp Pathol (2000) 1.22
Common variant near the endothelin receptor type A (EDNRA) gene is associated with intracranial aneurysm risk. Proc Natl Acad Sci U S A (2011) 1.08
Endothelin attenuates apoptosis in human smooth muscle cells. Biochem J (1997) 1.01
Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature (1999) 3.20
Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke (1998) 3.03
Differential selectivity of endothelium-derived relaxing factor and nitric oxide in smooth muscle. Br J Pharmacol (1987) 1.70
Inhibition of human platelet aggregation by S-nitrosothiols. Heme-dependent activation of soluble guanylate cyclase and stimulation of cyclic GMP accumulation. Mol Pharmacol (1983) 1.68
Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol (2000) 1.64
Extracellular signal-regulated kinase plays an essential role in hypertrophic agonists, endothelin-1 and phenylephrine-induced cardiomyocyte hypertrophy. J Biol Chem (2000) 1.60
SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia. J Pharmacol Exp Ther (2001) 1.54
In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation (2001) 1.46
Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat. Br J Pharmacol (2000) 1.45
Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemia. Med Res Rev (2001) 1.43
Purification and properties of heme-deficient hepatic soluble guanylate cyclase: effects of heme and other factors on enzyme activation by NO, NO-heme, and protoporphyrin IX. Arch Biochem Biophys (1982) 1.38
Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc Med (2000) 1.28
Interferon-inducible protein-10 involves vascular smooth muscle cell migration, proliferation, and inflammatory response. J Biol Chem (1996) 1.21
Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. Am J Physiol Heart Circ Physiol (2001) 1.18
Hypertensive end-organ damage and premature mortality are p38 mitogen-activated protein kinase-dependent in a rat model of cardiac hypertrophy and dysfunction. Circulation (2001) 1.13
Antihypertensive actions of the novel nonpeptide endothelin receptor antagonist SB 209670. Hypertension (1995) 1.11
Matrix metalloproteinase expression in cardiac myocytes following myocardial infarction in the rabbit. Life Sci (2001) 1.06
Studies on vascular dopamine receptors with the dopamine receptor agonist: SK&F 82526. J Pharmacol Exp Ther (1984) 1.05
Expression of endothelin-1, endothelin-3, endothelin-converting enzyme-1, and endothelin-A and endothelin-B receptor mRNA after angioplasty-induced neointimal formation in the rat. Circ Res (1996) 1.03
Osteopontin-stimulated vascular smooth muscle cell migration is mediated by beta 3 integrin. Exp Cell Res (1994) 1.02
Endothelin levels increase in rat focal and global ischemia. J Cereb Blood Flow Metab (1994) 1.02
Regional vasodilation to endothelin-1 is mediated by a non-ETA receptor subtype in the anaesthetized rat: effect of BQ-123 on systemic haemodynamic responses. Eur J Pharmacol (1992) 1.01
Human urotensin-II is a potent vasoactive peptide: pharmacological characterization in the rat, mouse, dog and primate. J Cardiovasc Pharmacol (2000) 1.01
Comparative pharmacology of endothelium-derived relaxing factor and nitric oxide. J Pharmacol Exp Ther (1988) 0.98
Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK&F 108566. J Pharmacol Exp Ther (1992) 0.97
Analysis of responses to endothelins in the rabbit pulmonary and systemic vascular beds. J Appl Physiol (1985) (1991) 0.97
The DA1 receptor agonist fenoldopam (SK & F 82526) is also an alpha 2-adrenoceptor antagonist. Eur J Pharmacol (1985) 0.96
Carvedilol inhibits vascular smooth muscle cell proliferation. J Cardiovasc Pharmacol (1993) 0.96
In vivo pharmacological characterization of the non-peptide endothelin receptor antagonist SB 209670. Br J Pharmacol (1995) 0.95
Cardiovascular effects of a new potent dopamine beta-hydroxylase inhibitor in spontaneously hypertensive rats. J Pharmacol Exp Ther (1987) 0.94
Cyclic guanosine monophosphate mediates vascular relaxation induced by atrial natriuretic factor. Hypertension (1985) 0.93
Neuron-specific enolase increases in cerebral and systemic circulation following focal ischemia. Brain Res (1993) 0.93
Pharmacological evidence for the presence of three distinct functional endothelin receptor subtypes in the rabbit lateral saphenous vein. Br J Pharmacol (1995) 0.93
Endothelin B receptor modulates inflammatory pain and cutaneous inflammation. Mol Pharmacol (1999) 0.93
Angiotensin type 1 receptors mediate smooth muscle proliferation and endothelin biosynthesis in rat vascular smooth muscle. J Pharmacol Exp Ther (1994) 0.92
Upregulated expression of human membrane type-5 matrix metalloproteinase in kidneys from diabetic patients. Am J Physiol Renal Physiol (2001) 0.91
SCH 23390 and SK&F 83566 are antagonists at vascular dopamine and serotonin receptors. Eur J Pharmacol (1985) 0.91
A comparison of carvedilol and metoprolol antioxidant activities in vitro. J Cardiovasc Pharmacol (2000) 0.91
A role for endogenous endothelin-1 in neointimal formation after rat carotid artery balloon angioplasty. Protective effects of the novel nonpeptide endothelin receptor antagonist SB 209670. Circ Res (1994) 0.90
Renal microvascular effects of endothelin. Am J Physiol (1990) 0.90
Human vascular vasopressin receptors: analysis with selective vasopressin receptor antagonists. J Pharmacol Exp Ther (1986) 0.89
Osteopontin expression in platelet-derived growth factor-stimulated vascular smooth muscle cells and carotid artery after balloon angioplasty. Arterioscler Thromb Vasc Biol (1996) 0.89
Substituted 1-benzylimidazole-2-thiols as potent and orally active inhibitors of dopamine beta-hydroxylase. J Med Chem (1986) 0.89
Signal transduction mechanisms mediating the vascular actions of endothelin. J Vasc Res (1997) 0.88
Tyr-129 is important to the peptide ligand affinity and selectivity of human endothelin type A receptor. Proc Natl Acad Sci U S A (1994) 0.87
Guanylate cyclase activation of nitroprusside and nitrosoguanidine is related to formation of S-nitrosothiol intermediates. Biochem Biophys Res Commun (1980) 0.87
In vitro and in vivo characterization of intrinsic sympathomimetic activity in normal and heart failure rats. J Pharmacol Exp Ther (1999) 0.87
Palosuran inhibits binding to primate UT receptors in cell membranes but demonstrates differential activity in intact cells and vascular tissues. Br J Pharmacol (2008) 0.86
BQ-123, a selective endothelin subtype A-receptor antagonist, lowers blood pressure in different rat models of hypertension. J Hypertens (1994) 0.86
Increased endothelin excretion in rats with renal failure induced by partial nephrectomy. Br J Pharmacol (1991) 0.85
Use of differential display to identify differentially expressed mRNAs induced by rat carotid artery balloon angioplasty. Lab Invest (1995) 0.84
Identification of endothelin receptor subtypes in human renal cortex and medulla using subtype-selective ligands. Endocrinology (1992) 0.84
Effect of endothelin on cortical microvascular perfusion in rats. Stroke (1990) 0.84
Expression of interleukin-1beta, interleukin-1 receptor, and interleukin-1 receptor antagonist mRNA in rat carotid artery after balloon angioplasty. Biochem Biophys Res Commun (2000) 0.83
Therapeutic modulation of transcription factor activity. Trends Pharmacol Sci (2001) 0.83
Nonpeptide endothelin antagonist. Cerebrovascular characterization and effects on delayed cerebral vasospasm. Stroke (1994) 0.83
Inhibitors of dopamine beta-hydroxylase. 3. Some 1-(pyridylmethyl)imidazole-2-thiones. J Med Chem (1987) 0.83
The effect of diltiazem on the coronary haemodynamic and cardiac functional effects produced by intracoronary administration of endothelin-1 in the anaesthetized dog. Br J Pharmacol (1990) 0.83
Expression of 14-3-3 gamma in injured arteries and growth factor- and cytokine-stimulated human vascular smooth muscle cells. Cell Growth Differ (1996) 0.82
Effect of nifedipine on cyclosporine A-induced nephrotoxicity, urinary endothelin excretion and renal endothelin receptor number. Eur J Pharmacol (1991) 0.82
Novel receptor antagonists welcome a new era in endothelin biology. Trends Pharmacol Sci (1994) 0.81
Selective ETA receptor antagonism with BQ-123 is insufficient to inhibit angioplasty induced neointima formation in the rat. Cardiovasc Res (1995) 0.81
Selective alterations in responsiveness of guanylate cyclase to activation by nitroso compounds during enzyme purification. Biochim Biophys Acta (1981) 0.81
Eprosartan reduces cardiac hypertrophy, protects heart and kidney, and prevents early mortality in severely hypertensive stroke-prone rats. Cardiovasc Res (2001) 0.81
Endothelial protective and antishock effects of a selective estrogen receptor modulator in rats. Am J Physiol Heart Circ Physiol (2001) 0.81
Dopamine-1 receptors in rat proximal convoluted tubule: regulation by intrarenal dopamine. Am J Physiol (1990) 0.81
Chronic carvedilol reduces mortality and renal damage in hypertensive stroke-prone rats. J Pharmacol Exp Ther (1996) 0.80
Comparison of bisoprolol and carvedilol cardioprotection in a rabbit ischemia and reperfusion model. Eur J Pharmacol (2000) 0.80
Apoptosis: a potential target for discovering novel therapies for cardiovascular diseases. Curr Opin Chem Biol (1999) 0.80
Pharmacology of eprosartan, an angiotensin II receptor antagonist: exploring hypotheses from clinical data. Am Heart J (1999) 0.80
Enrasentan improves survival, limits left ventricular remodeling, and preserves myocardial performance in hypertensive cardiac hypertrophy and dysfunction. J Cardiovasc Pharmacol (2001) 0.79
Evaluation of intrinsic sympathomimetic activity of bucindolol and carvedilol in rat heart. Pharmacology (1998) 0.79
Identification, characterization, and functional role of phosphodiesterase type IV in cerebral vessels: effects of selective phosphodiesterase inhibitors. J Cereb Blood Flow Metab (1997) 0.79
Nonpeptide endothelin receptor antagonists. I. Effects on binding and signal transduction on human endothelinA and endothelinB receptors. J Pharmacol Exp Ther (1994) 0.79
A diterpene epoxide from the marine brown alga Dictyota sp.: possible vasopressin V1 receptor antagonist. Phytochemistry (1993) 0.79
Selective antagonism of endothelin-A-receptors improves outcome in both head trauma and focal stroke in rat. J Cardiovasc Pharmacol (2000) 0.79
Targeted disruption of the endothelin-B-receptor gene attenuates inflammatory nociception and cutaneous inflammation in mice. J Cardiovasc Pharmacol (2000) 0.79
Enhanced pulmonary alpha-2 adrenoceptor responsiveness under conditions of elevated pulmonary vascular tone. J Pharmacol Exp Ther (1987) 0.79
Spinal endothelin content is elevated after moderate local trauma in the rat to levels associated with locomotor dysfunction after intrathecal injection. J Neurotrauma (1996) 0.79
Chronic hypoxia-induced cardiopulmonary changes in three rat strains: inhibition by the endothelin receptor antagonist SB 217242. J Cardiovasc Pharmacol (1998) 0.79
Nonpeptide endothelin receptor antagonists. VIII: attentuation of acute hypoxia-induced pulmonary hypertension in the dog. J Pharmacol Exp Ther (1997) 0.79
Platelet agonist F11 receptor is a member of the immunoglobulin superfamily and identical with junctional adhesion molecule (JAM): regulation of expression in human endothelial cells and macrophages. IUBMB Life (2000) 0.79
Activation of caspase-3/caspase-3-like activity in rat cardiomyocytes by an RGD peptide, but not the GPIIb/IIIa antagonist lotrafiban. Thromb Res (2001) 0.78
Antithrombotic effects of a platelet fibrinogen receptor antagonist in a canine model of carotid artery thrombosis. Stroke (1992) 0.78
SB 234551, a novel endothelin--A receptor antagonist, unmasks endothelin-induced renal vasodilatation in the dog. J Cardiovasc Pharmacol (1998) 0.78
Nonpeptide endothelin receptor antagonists. V: Prevention and reversal of acute renal failure in the rat by SB 209670. J Pharmacol Exp Ther (1995) 0.78
Functional evidence that balloon angioplasty results in transient nitric oxide synthase induction. Eur J Pharmacol (1994) 0.78
Endothelin-1 does not mediate hypoxic vasoconstriction in canine isolated blood vessels: effect of BQ-123. Br J Pharmacol (1993) 0.78
Nonpeptide endothelin receptor antagonists. III. Effect of SB 209670 and BQ123 on acute renal failure in anesthetized dogs. J Pharmacol Exp Ther (1994) 0.78
Selective estrogen receptor modulator idoxifene inhibits smooth muscle cell proliferation, enhances reendothelialization, and inhibits neointimal formation in vivo after vascular injury. Circulation (2000) 0.78
The endothelin receptor antagonist SB 217242 reduces cerebral focal ischemic brain injury. J Cardiovasc Pharmacol (1995) 0.78
Relationship between LTD4-induced endothelium-dependent vasomotor relaxation and cGMP. J Pharmacol Exp Ther (1988) 0.78
Factor XIIIa cross-links lipoprotein(a) with fibrinogen and is present in human atherosclerotic lesions. Circ Res (1998) 0.78
Plasma- and cerebrospinal fluid-immunoreactive endothelin-1: effects of nonpeptide endothelin receptor antagonists with diverse affinity profiles for endothelin-A and endothelin-B receptors. J Cardiovasc Pharmacol (1998) 0.77
Comparison of endothelin B (ETB) receptors in rabbit isolated pulmonary artery and bronchus. Br J Pharmacol (1996) 0.77
Temporal expression of ECE-1, ET-1, ET-3, ETA, and ETB receptor mRNAs after balloon angioplasty in the rat. J Cardiovasc Pharmacol (1995) 0.77
Tissue-type plasminogen activator and streptokinase induce platelet hyperaggregability in the rabbit. Thromb Res (1987) 0.77
Nonpeptide endothelin receptor antagonists: IV. Identification of receptors in rabbit colonic mucosa and smooth muscle and correlation with physiological effects. J Pharmacol Exp Ther (1995) 0.77